Defence Therapeutics Announces Warrant Terms Amendment

Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) announced an amendment to 800,000 Common Share purchase warrants issued in a 2024 private placement.

The amendment extends each warrant expiry by 12 months and reprices the exercise price to $0.75 per share (from $1.00). The split is 775,000 and 25,000 warrants with new expiries of October 30, 2027 and November 29, 2027 respectively. None have been exercised. All other warrant terms remain unchanged and the changes are subject to final approval of the Canadian Securities Exchange; compensation and finder warrants are not eligible for amendment.

Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:

No. of  Warrants:	Original Expiry Date of Warrants:	New Expiry Date of  Warrants:	Original Exercise Price of Warrants:	New Exercise Price of  Warrants:
775,000	October 30, 2026	October 30, 2027	$1.00	$0.75
25,000	November 29, 2026	November 29, 2027	$1.00	$0.75

 

None of the Warrants have been exercised as of the date hereof. All other terms of the Warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment. The amendments are subject to the final approval of the CSE.

About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum^® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.

For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289329

FAQ

What warrant changes did Defence Therapeutics (DTCFF) announce on March 20, 2026?

The company extended expiry dates by 12 months and repriced exercise to $0.75. According to the company, the amendment affects 800,000 warrants previously issued in 2024, split into 775,000 and 25,000 units with new expiries in October and November 2027.

How many Defence Therapeutics (DTCFF) warrants were repriced and what are the new expiries?

A total of 800,000 warrants were repriced to $0.75 and extended by 12 months. According to the company, 775,000 now expire October 30, 2027 and 25,000 now expire November 29, 2027.

Have any of the amended Defence Therapeutics (DTCFF) warrants been exercised?

No; none of the 800,000 warrants have been exercised as of the announcement date. According to the company, all other warrant terms remain unchanged pending final CSE approval.

Does the warrant amendment for Defence Therapeutics (DTCFF) include finder or compensation warrants?

No; compensation and finder warrants are not eligible for amendment under CSE rules. According to the company, only eligible warrants from the 2024 placement were amended and changes require CSE final approval.

Is the Defence Therapeutics (DTCFF) warrant amendment final or conditional?

The amendment is conditional and subject to final approval by the Canadian Securities Exchange. According to the company, the repricing and extension will take effect only after receiving the CSE's final approval.